AEZS.TO लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 23:28):

Stats
आज की मात्रा	445.00
औसत मात्रा	559.00
बाजार मूल्य	13.77M
EPS	$0 ( 2024-05-06 )
Last Dividend	$0.0825 ( 1999-08-11 )
Next Dividend	$0 ( N/A )
P/E	-0.610
ATR14	$0 (0.00%)

AETERNA ZENTARIS INC सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
HZM.TO	0.971
IGM.TO	0.958
BRE.TO	0.958
SOLG.TO	0.957
D-UN.TO	0.956
SGR-UN.TO	0.956
CVD.TO	0.954
AP-UN.TO	0.95
TRZ.TO	0.949
MPCT-UN.TO	0.949

10 सबसे अधिक नकारात्मक सहसंबंध
QBTL.TO	-0.93
SBB.TO	-0.919
SNC.TO	-0.915
IAF-PI.TO	-0.915
SFC.TO	-0.902
E.TO	-0.895
PEY.TO	-0.894
RQK.TO	-0.889
U-UN.TO	-0.878
VLE.TO	-0.865

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

AETERNA ZENTARIS INC वित्तीय

Annual	2023
राजस्व:	$4.50M
सकल लाभ:	$4.28M (95.06 %)
EPS:	$-3.41

FY	2023
राजस्व:	$4.50M
सकल लाभ:	$4.28M (95.06 %)
EPS:	$-3.41

FY	2022
राजस्व:	$5.64M
सकल लाभ:	$5.48M (97.22 %)
EPS:	$-6.22

FY	2021
राजस्व:	$5.26M
सकल लाभ:	$5.17M (98.29 %)
EPS:	$-1.820

Financial Reports:

No articles found.

AETERNA ZENTARIS INC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

AETERNA ZENTARIS INC Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0825	1999-08-11
Last Dividend	$0.0825	1999-08-11
Next Dividend	$0	N/A
Payout Date	2007-01-02
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0825	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-07)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
1999	$0	0.00%
2000	$0	0.00%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for TSX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
ZPL.TO	Dividend Knight	2023-08-29	Monthly	12	2.01%
THE.TO	Dividend Junior	2023-06-28	Quarterly	9	1.44%
KEG-UN.TO	Dividend Royal	2023-09-20	Monthly	17	3.95%
CLF.TO	Dividend King	2023-09-25	Monthly	17	1.24%
XID.TO	Dividend Junior	2023-06-26	Annually	15	1.67%
PXC.TO	Dividend Junior	2023-06-28	Quarterly	13	1.74%
FLGD.TO	Dividend Knight	2023-08-31	Monthly	7	1.99%
UMI.TO	Dividend Junior	2023-06-23	Quarterly	7	1.34%
MKB.TO	Dividend Knight	2023-09-01	Monthly	9	1.44%
CWB.TO	Dividend King	2023-06-07	Quarterly	30	2.18%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-3.70	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.450	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.636	1.500	-8.18	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	8.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.57	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	7.49	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00754	-1.500	9.87	-10.00	[0 - 0.6]
interestCoverageTTM	-375.17	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-3.52	2.00	-1.175	-2.35	[0 - 30]
freeCashFlowPerShareTTM	-3.53	2.00	-1.764	-3.53	[0 - 20]
debtEquityRatioTTM	0.0153	-1.500	9.94	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.951	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-4.00	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-61.35	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.122	0.800	-2.52	-2.02	[0.5 - 2]
Total Score				-1.290

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.28	1.000	-0.332	0	[1 - 100]
returnOnEquityTTM	-0.636	2.50	-5.26	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-3.53	2.00	-1.176	-3.53	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.52	2.00	-1.175	-2.35	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.723	1.500	1.849	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.81	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.23

AETERNA ZENTARIS INC

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.